Kriska BioTech ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  29.9% 16.4% 16.3% 20.1% 21.8%  
Credit score (0-100)  2 11 10 5 3  
Credit rating  C BB BB B B  
Credit limit (kDKK)  -0.0 -0.0 -0.0 -0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9

Net sales  0 0 0 -25 0  
Gross profit  -33.4 -27.3 38.9 -87.5 -26.0  
EBITDA  -175 -32.2 33.5 -87.8 -26.0  
EBIT  -186 -50.9 4.6 -125 -54.6  
Pre-tax profit (PTP)  -189.9 -55.1 0.1 -120.3 -61.3  
Net earnings  -175.3 -55.1 0.1 -120.3 -61.3  
Pre-tax profit without non-rec. items  -190 -55.1 0.1 -120 -61.3  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9

Tangible assets total  96.0 85.3 74.6 63.9 53.2  
Shareholders equity total  -94.5 -150 -149 -270 -331  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  241 272 334 202 159  

Net Debt  -56.2 -32.2 -99.9 -7.3 -3.0  
 
See the entire balance sheet

Volume 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9

Net sales  0 0 0 -25 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% -100.0%  
Gross profit  -33.4 -27.3 38.9 -87.5 -26.0  
Gross profit growth  0.0% 18.2% 0.0% 0.0% 70.2%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  241 272 334 202 159  
Balance sheet change%  -29.4% 13.0% 22.9% -39.6% -21.4%  
Added value  -175.5 -32.2 33.5 -95.8 -26.0  
Added value %  0.0% 0.0% 0.0% 385.1% 0.0%  
Investments  -21 14 2 -66 -57  

Net sales trend  0.0 0.0 0.0 0.0 -1.0  
EBIT trend  -1.0 -2.0 1.0 -1.0 -2.0  

Profitability 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
EBITDA %  0.0% 0.0% 0.0% 352.9% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  556.1% 186.2% 11.7% 142.6% 209.5%  
Net Earnings %  0.0% 0.0% 0.0% 483.5% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 335.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 483.5% 0.0%  
ROA %  -55.0% -13.5% 1.0% -26.1% -11.4%  
ROI %  -389.4% 0.0% 0.0% 0.0% 0.0%  
ROE %  -109.1% -21.5% 0.0% -44.9% -34.0%  

Solidity 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Equity ratio %  -28.2% -35.5% -30.9% -57.2% -67.6%  
Relative indebtedness %  0.0% 0.0% 0.0% -1,895.6% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% -1,866.4% 0.0%  
Net int. bear. debt to EBITDA, %  32.0% 99.9% -298.1% 8.3% 11.6%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Quick Ratio  0.2 0.2 0.2 0.0 0.0  
Current Ratio  0.3 0.2 0.3 0.0 0.0  
Cash and cash equivalent  56.2 32.2 99.9 7.3 3.0  

Capital use efficiency 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Trade debtors turnover (days)  0.0 0.0 0.0 -94.1 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% -71.1% 0.0%  
Net working capital  -244.6 -332.3 -362.7 -454.0 -486.8  
Net working capital %  0.0% 0.0% 0.0% 1,824.6% 0.0%  

Employee efficiency 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0